lenvatinib 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
tyrosine kinase inhibitors	4942	417716-92-8

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: E-7080 E 7080 lenvatinib lenvima ER-203492-00 E7080 lenvatinib mesylate lenvatinib mesilate	a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4) Molecular weight: 426.86 Formula: C21H19ClN4O4 CLOGP: 3.05 LIPINSKI: 0 HAC: 8 HDO: 3 TPSA: 115.57 ALOGS: -4.84 ROTB: 6 Status: ONP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

E-7080
E 7080
lenvatinib
lenvima
ER-203492-00
E7080
lenvatinib mesylate
lenvatinib mesilate

a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4)

Molecular weight: 426.86
Formula: C21H19ClN4O4
CLOGP: 3.05
LIPINSKI: 0
HAC: 8
HDO: 3
TPSA: 115.57
ALOGS: -4.84
ROTB: 6

Status: ONP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
18	mg	O

ADMET properties:

None

Approvals:

Date	Agency	Company
March 26, 2015	PMDA	Eisai Co., Ltd.
Feb. 13, 2015	FDA	EISAI INC
May 28, 2015	EMA	Eisai Europe Ltd

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hypertension	1274.04	24.88	768	12954	243510	56034835
Malignant neoplasm progression	1097.02	24.88	472	13250	73115	56205230
Proteinuria	716.42	24.88	236	13486	17334	56261011
Palmar-plantar erythrodysaesthesia syndrome	506.10	24.88	191	13531	20874	56257471
Hypothyroidism	496.23	24.88	223	13499	37973	56240372
Decreased appetite	483.54	24.88	410	13312	218821	56059524
Platelet count decreased	395.44	24.88	272	13450	106111	56172234
Diarrhoea	245.96	24.88	502	13220	638005	55640340
Hepatic encephalopathy	236.55	24.88	90	13632	10020	56268325
Immune-mediated hypothyroidism	173.50	24.88	31	13691	143	56278202
Blood pressure increased	165.59	24.88	190	13532	144986	56133359
Cholecystitis	137.05	24.88	68	13654	14367	56263978
Dysphonia	136.27	24.88	99	13623	41848	56236497
Drug ineffective	133.08	24.88	31	13691	918958	55359387
Malaise	115.15	24.88	267	13455	367593	55910752
Blood thyroid stimulating hormone increased	106.82	24.88	45	13677	6518	56271827
Hepatic function abnormal	106.44	24.88	79	13643	34479	56243866
Gastrointestinal perforation	98.97	24.88	35	13687	3164	56275181
Stomatitis	97.36	24.88	133	13589	120677	56157668
Tumour haemorrhage	94.54	24.88	28	13694	1436	56276909
Hyperthyroidism	92.68	24.88	51	13671	13301	56265044
Fistula	84.88	24.88	42	13680	8813	56269532
Rheumatoid arthritis	80.25	24.88	3	13719	382601	55895744
Pneumothorax	77.13	24.88	47	13675	14820	56263525
Pyrexia	75.00	24.88	248	13474	418525	55859820
Ascites	73.67	24.88	66	13656	37478	56240867
Tracheal fistula	65.53	24.88	11	13711	32	56278313
Fatigue	65.03	24.88	369	13353	788183	55490162
Renal impairment	63.67	24.88	88	13634	80625	56197720
Thrombocytopenia	62.56	24.88	116	13606	136108	56142237
Condition aggravated	62.46	24.88	6	13716	344892	55933453
Cerebral haemorrhage	55.54	24.88	50	13672	28556	56249789
Immune-mediated hepatic disorder	54.91	24.88	13	13709	276	56278069
Posterior reversible encephalopathy syndrome	54.83	24.88	39	13683	15921	56262424
Cardiac failure	53.81	24.88	82	13640	82011	56196334
Drug hypersensitivity	51.95	24.88	4	13718	275201	56003144
Dehydration	51.33	24.88	117	13605	158708	56119637
Hypersensitivity	50.52	24.88	3	13719	256405	56021940
Intestinal perforation	50.16	24.88	32	13690	10927	56267418
Protein urine present	48.76	24.88	25	13697	5651	56272694
Colitis	47.98	24.88	55	13667	41756	56236589
Weight decreased	46.97	24.88	147	13575	240567	56037778
Large intestine perforation	46.40	24.88	27	13695	7824	56270521
Oral pain	45.31	24.88	43	13679	26250	56252095
Cholecystitis acute	45.15	24.88	26	13696	7390	56270955
Nephrotic syndrome	44.53	24.88	23	13699	5277	56273068
Swelling	43.83	24.88	4	13718	239767	56038578
Arterial haemorrhage	43.58	24.88	16	13706	1609	56276736
Thyroid disorder	43.19	24.88	32	13690	13906	56264439
Immune-mediated hepatitis	42.15	24.88	14	13708	1047	56277298
Weight increased	41.54	24.88	4	13718	229699	56048646
Pain	40.61	24.88	62	13660	663122	55615223
Oesophageal fistula	40.30	24.88	9	13713	146	56278199
Infusion related reaction	39.52	24.88	3	13719	208928	56069417
Off label use	39.07	24.88	47	13675	556133	55722212
Myocarditis	38.41	24.88	25	13697	8833	56269512
Vomiting	38.11	24.88	229	13493	497999	55780346
Toxicity to various agents	37.87	24.88	5	13717	224559	56053786
Thyroiditis	36.52	24.88	15	13707	2037	56276308
Tracheal haemorrhage	34.53	24.88	8	13714	154	56278191
Female genital tract fistula	33.50	24.88	18	13704	4474	56273871
Epistaxis	33.16	24.88	59	13663	66964	56211381
Arthropathy	32.50	24.88	5	13717	200270	56078075
Hypertensive crisis	32.22	24.88	27	13695	14009	56264336
Hyponatraemia	31.59	24.88	74	13648	102065	56176280
Joint swelling	30.99	24.88	16	13706	289784	55988561
Peritonitis	30.81	24.88	28	13694	16174	56262171
Nausea	30.21	24.88	301	13421	763877	55514468
Drug intolerance	29.25	24.88	14	13708	264804	56013541
Fall	28.64	24.88	27	13695	357483	55920862
Eastern Cooperative Oncology Group performance status worsened	28.49	24.88	10	13712	883	56277462
Renal cancer	28.17	24.88	17	13705	5262	56273083
Sinusitis	27.72	24.88	7	13715	197574	56080771
Alopecia	27.45	24.88	19	13703	293439	55984906
Product dose omission issue	27.33	24.88	8	13714	204745	56073600
Taste disorder	27.21	24.88	21	13701	9694	56268651
Primary adrenal insufficiency	25.23	24.88	6	13716	130	56278215

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Decreased appetite	765.61	22.32	608	14434	152609	31529693
Hepatic encephalopathy	741.77	22.32	269	14773	13402	31668900
Malignant neoplasm progression	736.80	22.32	460	14582	78538	31603764
Proteinuria	560.16	22.32	232	14810	16531	31665771
Palmar-plantar erythrodysaesthesia syndrome	546.96	22.32	223	14819	15260	31667042
Hypertension	530.96	22.32	457	14585	127643	31554659
Diarrhoea	369.28	22.32	622	14420	351787	31330515
Hypothyroidism	278.02	22.32	146	14896	17801	31664501
Tumour haemorrhage	221.43	22.32	72	14970	2556	31679746
Liver carcinoma ruptured	183.54	22.32	36	15006	135	31682167
Fatigue	160.17	22.32	431	14611	334775	31347527
Dysphonia	142.61	22.32	100	14942	20491	31661811
Blood pressure increased	137.86	22.32	179	14863	79454	31602848
Malaise	132.41	22.32	264	14778	168247	31514055
Oesophageal varices haemorrhage	124.59	22.32	48	14994	2812	31679490
Ascites	112.64	22.32	117	14925	40896	31641406
Cholecystitis	105.85	22.32	63	14979	9754	31672548
Drug ineffective	103.54	22.32	30	15012	395543	31286759
Hepatic failure	98.35	22.32	98	14944	32604	31649698
Ammonia increased	94.95	22.32	44	14998	4083	31678219
Stomatitis	93.32	22.32	104	14938	39334	31642968
Hepatic function abnormal	87.89	22.32	103	14939	41119	31641183
Cholangitis	82.85	22.32	50	14992	7936	31674366
Pneumothorax	77.02	22.32	64	14978	16846	31665456
Blood bilirubin increased	75.23	22.32	88	14954	35048	31647254
Blood thyroid stimulating hormone increased	67.01	22.32	33	15009	3504	31678798
Dehydration	64.41	22.32	161	14881	118950	31563352
Oral pain	64.27	22.32	46	14996	9719	31672583
Tumour rupture	58.27	22.32	15	15027	226	31682076
Tracheal fistula	54.81	22.32	12	15030	85	31682217
Drug interaction	54.04	22.32	16	15026	208527	31473775
Toxicity to various agents	52.68	22.32	11	15031	181476	31500826
Condition aggravated	51.79	22.32	8	15034	164001	31518301
Epistaxis	50.45	22.32	91	14951	53616	31628686
Platelet count decreased	50.23	22.32	140	14902	110295	31572007
Off label use	48.75	22.32	56	14986	347218	31335084
Portal vein thrombosis	47.15	22.32	26	15016	3481	31678821
Weight decreased	45.74	22.32	173	14869	159779	31522523
Gastrointestinal perforation	43.60	22.32	25	15017	3607	31678695
Hyperammonaemia	41.92	22.32	29	15013	5804	31676498
Vomiting	41.74	22.32	213	14829	223760	31458542
Renal cancer	41.20	22.32	32	15010	7647	31674655
Cholecystitis acute	37.90	22.32	27	15015	5660	31676642
Immune-mediated hepatitis	35.16	22.32	17	15025	1733	31680569
Thyroiditis	34.75	22.32	18	15024	2125	31680177
Adrenal insufficiency	34.50	22.32	36	15006	12623	31669679
Interstitial lung disease	33.12	22.32	83	14959	61320	31620982
Tracheo-oesophageal fistula	32.75	22.32	11	15031	432	31681870
Completed suicide	32.47	22.32	3	15039	91511	31590791
Protein urine present	31.96	22.32	23	15019	4897	31677405
Pneumonitis	31.43	22.32	54	14988	30598	31651704
Taste disorder	31.30	22.32	24	15018	5626	31676676
Rhythm idioventricular	28.89	22.32	9	15033	277	31682025
Liver abscess	28.72	22.32	19	15023	3532	31678770
Nausea	28.06	22.32	245	14797	307702	31374600
Neutropenia	27.88	22.32	16	15026	140348	31541954
Arterial haemorrhage	25.85	22.32	11	15031	833	31681469
Protein induced by vitamin K absence or antagonist II increased	25.65	22.32	5	15037	18	31682284
Liver disorder	24.95	22.32	48	14994	29659	31652643
Haemobilia	23.70	22.32	8	15034	319	31681983
Cholangitis acute	23.22	22.32	10	15032	780	31681522
Nephrotic syndrome	22.92	22.32	22	15020	6981	31675321
Overdose	22.81	22.32	6	15036	84658	31597644

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Malignant neoplasm progression	1437.25	22.23	705	20322	121034	70786383
Hypertension	1394.34	22.23	940	20087	295093	70612324
Proteinuria	995.27	22.23	361	20666	29013	70878404
Decreased appetite	872.19	22.23	719	20308	304061	70603356
Palmar-plantar erythrodysaesthesia syndrome	803.03	22.23	311	20716	29936	70877481
Hepatic encephalopathy	671.86	22.23	251	20776	21867	70885550
Hypothyroidism	561.73	22.23	273	20754	45482	70861935
Diarrhoea	375.21	22.23	756	20271	782585	70124832
Tumour haemorrhage	294.25	22.23	87	20940	3635	70903782
Platelet count decreased	277.03	22.23	301	20726	177921	70729496
Cholecystitis	199.53	22.23	105	20922	20596	70886821
Drug ineffective	187.77	22.23	28	20999	939724	69967693
Malaise	168.97	22.23	386	20641	432546	70474871
Hepatic function abnormal	165.61	22.23	147	20880	67849	70839568
Pneumothorax	162.19	22.23	99	20928	25747	70881670
Dysphonia	152.16	22.23	123	20904	49977	70857440
Immune-mediated hypothyroidism	150.11	22.23	32	20995	334	70907083
Ascites	141.05	22.23	134	20893	67413	70840004
Liver carcinoma ruptured	135.86	22.23	26	21001	148	70907269
Blood pressure increased	128.46	22.23	213	20814	188304	70719113
Blood thyroid stimulating hormone increased	120.39	22.23	56	20971	8423	70898994
Oesophageal varices haemorrhage	114.74	22.23	43	20984	3760	70903657
Tracheal fistula	110.42	22.23	21	21006	115	70907302
Gastrointestinal perforation	94.81	22.23	42	20985	5639	70901778
Blood bilirubin increased	92.49	22.23	101	20926	59800	70847617
Condition aggravated	89.20	22.23	11	21016	427624	70479793
Dehydration	84.97	22.23	199	20828	225943	70681474
Fistula	82.18	22.23	47	20980	10834	70896583
Stomatitis	80.55	22.23	140	20887	128371	70779046
Cholecystitis acute	80.53	22.23	48	20979	11946	70895471
Toxicity to various agents	79.28	22.23	10	21017	382162	70525255
Immune-mediated hepatitis	74.25	22.23	29	20998	2837	70904580
Hyperthyroidism	73.27	22.23	55	20972	20036	70887381
Pyrexia	73.21	22.23	364	20663	606588	70300829
Tracheo-oesophageal fistula	71.37	22.23	19	21008	537	70906880
Fatigue	69.52	22.23	449	20578	823870	70083547
Hepatic failure	68.58	22.23	85	20942	57540	70849877
Arterial haemorrhage	68.17	22.23	26	21001	2385	70905032
Nephrotic syndrome	64.79	22.23	40	20987	10600	70896817
Cholangitis	64.25	22.23	41	20986	11508	70895909
Ammonia increased	62.55	22.23	34	20993	7104	70900313
Cerebral haemorrhage	60.19	22.23	77	20950	53787	70853630
Renal impairment	59.93	22.23	132	20895	143805	70763612
Large intestine perforation	59.28	22.23	41	20986	13154	70894263
Off label use	56.72	22.23	83	20944	742977	70164440
Weight increased	56.40	22.23	4	21023	242327	70665090
Vomiting	56.09	22.23	333	20694	592778	70314639
Hypersensitivity	55.86	22.23	3	21024	229809	70677608
Drug interaction	55.26	22.23	22	21005	381419	70525998
Oesophageal fistula	53.67	22.23	14	21013	365	70907052
Thyroiditis	52.20	22.23	25	21002	4011	70903406
Drug hypersensitivity	51.73	22.23	8	21019	262451	70644966
Posterior reversible encephalopathy syndrome	50.11	22.23	48	20979	24354	70883063
Intestinal perforation	49.96	22.23	40	20987	16004	70891413
Cardiac failure	49.20	22.23	122	20905	143419	70763998
Colitis	48.68	22.23	76	20951	63738	70843679
Hyperammonaemia	48.64	22.23	33	20994	10260	70897157
Portal vein thrombosis	48.26	22.23	26	21001	5336	70902081
Hypertensive crisis	47.55	22.23	42	20985	19220	70888197
Protein urine present	46.37	22.23	31	20996	9409	70898008
Pneumonitis	45.86	22.23	68	20959	54529	70852888
Weight decreased	45.21	22.23	197	20830	310291	70597126
Adrenal insufficiency	45.13	22.23	46	20981	25149	70882268
Pain	44.35	22.23	74	20953	628742	70278675
Infusion related reaction	43.90	22.23	4	21023	197530	70709887
Cerebral infarction	41.16	22.23	57	20970	42952	70864465
Fall	40.73	22.23	43	20984	444053	70463364
Immune-mediated hepatic disorder	40.72	22.23	14	21013	954	70906463
Epistaxis	40.32	22.23	92	20935	102535	70804882
Product dose omission issue	39.85	22.23	8	21019	217460	70689957
Sinusitis	38.76	22.23	3	21024	169192	70738225
Interstitial lung disease	38.02	22.23	91	20936	104594	70802823
Haemoptysis	37.47	22.23	60	20967	51392	70856025
Hyponatraemia	37.06	22.23	118	20909	159969	70747448
Primary adrenal insufficiency	36.40	22.23	9	21018	188	70907229
Drug intolerance	36.12	22.23	11	21016	225676	70681741
Upper gastrointestinal haemorrhage	34.86	22.23	49	20978	37428	70869989
Tumour rupture	34.69	22.23	10	21017	381	70907036
Abdominal pain	34.10	22.23	195	20832	341932	70565485
Small intestinal perforation	34.01	22.23	17	21010	2992	70904425
Tumour lysis syndrome	32.92	22.23	36	20991	21324	70886093
Joint swelling	32.90	22.23	17	21010	253194	70654223
Immune-mediated myocarditis	32.76	22.23	11	21016	697	70906720
Overdose	31.61	22.23	6	21021	169739	70737678
Arthropathy	30.89	22.23	4	21023	150053	70757364
Female genital tract fistula	30.62	22.23	16	21011	3087	70904330
Swelling	30.51	22.23	9	21018	188530	70718887
Eastern Cooperative Oncology Group performance status worsened	30.46	22.23	13	21014	1595	70905822
Pulmonary embolism	29.99	22.23	108	20919	155759	70751658
Treatment failure	29.29	22.23	4	21023	144138	70763279
Oesophageal perforation	29.26	22.23	12	21015	1332	70906085
Musculoskeletal stiffness	27.99	22.23	5	21022	147755	70759662
Insomnia	27.73	22.23	15	21012	217791	70689626
Rhythm idioventricular	27.62	22.23	9	21018	519	70906898
Duodenal perforation	27.49	22.23	13	21014	2027	70905390
Liver disorder	27.35	22.23	58	20969	61510	70845907
Nasopharyngitis	27.29	22.23	16	21011	222190	70685227
Depression	26.38	22.23	13	21014	198961	70708456
Cancer pain	26.36	22.23	17	21010	4857	70902560
Tracheal haemorrhage	25.87	22.23	9	21018	635	70906782
Cholangitis acute	25.47	22.23	11	21016	1389	70906028
Immune-mediated renal disorder	24.96	22.23	6	21021	111	70907306
Malignant pleural effusion	24.89	22.23	14	21013	3125	70904292
Injection site pain	24.53	22.23	3	21024	117616	70789801
Taste disorder	24.52	22.23	23	21004	11362	70896055
Pancreatitis	24.40	22.23	56	20971	62612	70844805
Urticaria	24.25	22.23	9	21018	163040	70744377
Liver abscess	24.22	22.23	17	21010	5582	70901835
Tumour pain	24.14	22.23	12	21015	2086	70905331
Oral pain	24.11	22.23	36	20991	29030	70878387
Peritonitis	24.02	22.23	34	20993	26125	70881292
Hyperhidrosis	23.77	22.23	5	21022	131581	70775836
Paraesthesia	23.45	22.23	7	21020	145530	70761887
Asthma	23.07	22.23	4	21023	120789	70786628
Hepatic rupture	22.74	22.23	5	21022	61	70907356
Amylase increased	22.72	22.23	21	21006	10187	70897230
Pneumonia aspiration	22.44	22.23	54	20973	62235	70845182

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L01EX08	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS PROTEIN KINASE INHIBITORS Other protein kinase inhibitors
FDA MoA	N0000020000	Receptor Tyrosine Kinase Inhibitors
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D047428	Protein Kinase Inhibitors
FDA EPC	N0000175605	Kinase Inhibitor
CHEBI has role	CHEBI:35610	antineoplastic agents
CHEBI has role	CHEBI:62434	ALK inhibitor
CHEBI has role	CHEBI:63457	FGFR inhibitors
CHEBI has role	CHEBI:65207	vascular endothelial growth factor receptor inhibitors
CHEBI has role	CHEBI:71031	orphan drugs

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Endometrial carcinoma progressing after chemotherapy	indication	254878006	DOID:2871
Follicular thyroid carcinoma	indication	255028004	DOID:3962
Papillary thyroid carcinoma	indication	255029007	DOID:3969
Renal cell carcinoma	indication	702391001	DOID:4450
Thymic carcinoma	indication	722670005

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	12.09	acidic
pKa2	12.74	acidic
pKa3	13.02	acidic
pKa4	4.67	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
EQ 10MG BASE	LENVIMA	EISAI INC	N206947	Feb. 13, 2015	RX	CAPSULE	ORAL	9006256	July 27, 2027	METHOD FOR TREATING THYROID CARCINOMA INCLUDING DIFFERENTIATED THYROID CANCER
EQ 4MG BASE	LENVIMA	EISAI INC	N206947	Feb. 13, 2015	RX	CAPSULE	ORAL	9006256	July 27, 2027	METHOD FOR TREATING THYROID CARCINOMA INCLUDING DIFFERENTIATED THYROID CANCER

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
EQ 10MG BASE	LENVIMA	EISAI INC	N206947	Feb. 13, 2015	RX	CAPSULE	ORAL	Feb. 13, 2022	TREATMENT OF PATIENTS WITH LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, RADIOACTIVE IODINE REFRACTORY DIFFERENTIATED THYROID CANCER
EQ 4MG BASE	LENVIMA	EISAI INC	N206947	Feb. 13, 2015	RX	CAPSULE	ORAL	Feb. 13, 2022	TREATMENT OF PATIENTS WITH LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, RADIOACTIVE IODINE REFRACTORY DIFFERENTIATED THYROID CANCER
EQ 10MG BASE	LENVIMA	EISAI INC	N206947	Feb. 13, 2015	RX	CAPSULE	ORAL	Sept. 17, 2022	TREATMENT OF ADVANCED ENDOMETRIAL CARCINOMA THAT IS NOT MICROSATELLITE INSTABILITY-HIGH OR MISMATCH REPAIR DEFICIENT, WHO HAVE DISEASE PROGRESSION FOLLOWING PRIOR SYSTEMIC THERAPY AND ARE NOT CANDIDATES FOR CURATIVE SURGERY OR RADIATION
EQ 4MG BASE	LENVIMA	EISAI INC	N206947	Feb. 13, 2015	RX	CAPSULE	ORAL	Sept. 17, 2022	TREATMENT OF ADVANCED ENDOMETRIAL CARCINOMA THAT IS NOT MICROSATELLITE INSTABILITY-HIGH OR MISMATCH REPAIR DEFICIENT, WHO HAVE DISEASE PROGRESSION FOLLOWING PRIOR SYSTEMIC THERAPY AND ARE NOT CANDIDATES FOR CURATIVE SURGERY OR RADIATION
EQ 10MG BASE	LENVIMA	EISAI INC	N206947	Feb. 13, 2015	RX	CAPSULE	ORAL	July 21, 2024	REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY 309/KEYNOTE-775 TO SUPPORT PMR 3696-1 AND 3700-1
EQ 4MG BASE	LENVIMA	EISAI INC	N206947	Feb. 13, 2015	RX	CAPSULE	ORAL	July 21, 2024	REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY 309/KEYNOTE-775 TO SUPPORT PMR 3696-1 AND 3700-1
EQ 10MG BASE	LENVIMA	EISAI INC	N206947	Feb. 13, 2015	RX	CAPSULE	ORAL	Aug. 10, 2024	LENVATINIB IN COMBINATION WITH PEMBROLIZUMAB, IS INDICATED FOR THE FIRST-LINE TREATMENT OF ADULT PATIENTS WITH ADVANCED RENAL CELL CARCINOMA (RCC)
EQ 4MG BASE	LENVIMA	EISAI INC	N206947	Feb. 13, 2015	RX	CAPSULE	ORAL	Aug. 10, 2024	LENVATINIB IN COMBINATION WITH PEMBROLIZUMAB, IS INDICATED FOR THE FIRST-LINE TREATMENT OF ADULT PATIENTS WITH ADVANCED RENAL CELL CARCINOMA (RCC)
EQ 10MG BASE	LENVIMA	EISAI INC	N206947	Feb. 13, 2015	RX	CAPSULE	ORAL	Dec. 19, 2024	REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY E7080-G000-211 TO SUPPORT PMR 2865-1
EQ 4MG BASE	LENVIMA	EISAI INC	N206947	Feb. 13, 2015	RX	CAPSULE	ORAL	Dec. 19, 2024	REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY E7080-G000-211 TO SUPPORT PMR 2865-1
EQ 10MG BASE	LENVIMA	EISAI INC	N206947	Feb. 13, 2015	RX	CAPSULE	ORAL	Aug. 15, 2025	INDICATED FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC)
EQ 4MG BASE	LENVIMA	EISAI INC	N206947	Feb. 13, 2015	RX	CAPSULE	ORAL	Aug. 15, 2025	INDICATED FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC)

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Proto-oncogene tyrosine-protein kinase receptor Ret	Kinase	P07949	RET_HUMAN	INHIBITOR	Ki	8.82	CHEMBL	DRUG LABEL
Mast/stem cell growth factor receptor Kit	Kinase	P10721	KIT_HUMAN	INHIBITOR	IC50	7	SCIENTIFIC LITERATURE	DRUG LABEL
Vascular endothelial growth factor receptor 1	Kinase	P17948	VGFR1_HUMAN	INHIBITOR	IC50	7.66	SCIENTIFIC LITERATURE	DRUG LABEL
Vascular endothelial growth factor receptor 2	Kinase	P35968	VGFR2_HUMAN	INHIBITOR	IC50	8.40	SCIENTIFIC LITERATURE	DRUG LABEL
Vascular endothelial growth factor receptor 3	Kinase	P35916	VGFR3_HUMAN	INHIBITOR	IC50	8.28	SCIENTIFIC LITERATURE	DRUG LABEL
Platelet-derived growth factor receptor alpha	Kinase	P16234	PGFRA_HUMAN	INHIBITOR	IC50	7.29	SCIENTIFIC LITERATURE	DRUG LABEL
Fibroblast growth factor receptor 1	Kinase	P11362	FGFR1_HUMAN	INHIBITOR	IC50	7.34	SCIENTIFIC LITERATURE	DRUG LABEL
Mitogen-activated protein kinase kinase kinase kinase 5	Kinase	Q9Y4K4	M4K5_HUMAN		Kd	5.51	CHEMBL
Receptor-interacting serine/threonine-protein kinase 2	Kinase	O43353	RIPK2_HUMAN		Kd	7.96	CHEMBL
STE20-like serine/threonine-protein kinase	Kinase	Q9H2G2	SLK_HUMAN		Kd	5.41	CHEMBL
Epithelial discoidin domain-containing receptor 1	Kinase	Q08345	DDR1_HUMAN		Kd	7.34	CHEMBL
Protein-tyrosine kinase 6	Kinase	Q13882	PTK6_HUMAN		Kd	6.76	CHEMBL
MAP kinase-activated protein kinase 2	Kinase	P49137	MAPK2_HUMAN		Kd	7.20	CHEMBL
Discoidin domain-containing receptor 2	Kinase	Q16832	DDR2_HUMAN		Kd	6.66	CHEMBL
Aurora kinase B	Kinase	Q96GD4	AURKB_HUMAN		Kd	5.75	CHEMBL
Ribosyldihydronicotinamide dehydrogenase [quinone]	Enzyme	P16083	NQO2_HUMAN		Kd	5.82	CHEMBL
Serine/threonine-protein kinase/endoribonuclease IRE1	Kinase	O75460	ERN1_HUMAN		Kd	5.65	CHEMBL
Dual specificity mitogen-activated protein kinase kinase 5	Kinase	Q13163	MP2K5_HUMAN		Kd	5.54	CHEMBL
Ferrochelatase, mitochondrial	Enzyme	P22830	HEMH_HUMAN		Kd	5.55	CHEMBL
Receptor-interacting serine/threonine-protein kinase 3	Kinase	Q9Y572	RIPK3_HUMAN		Kd	6.50	CHEMBL
Mitogen-activated protein kinase kinase kinase 6	Kinase	O95382	M3K6_HUMAN		Kd	5.80	CHEMBL
Platelet-derived growth factor receptor beta	Kinase	P09619	PGFRB_HUMAN	INHIBITOR	IC50	7.41	SCIENTIFIC LITERATURE
Epidermal growth factor receptor	Kinase	P00533	EGFR_HUMAN	INHIBITOR	IC50	5.19	SCIENTIFIC LITERATURE
Mitogen-activated protein kinase kinase kinase kinase 2	Kinase	Q12851	M4K2_HUMAN		Kd	6.24	CHEMBL
Tyrosine-protein kinase ABL1	Kinase	P00519	ABL1_HUMAN		Kd	5.42	CHEMBL
Carbonic anhydrase 5A, mitochondrial	Enzyme	P35218	CAH5A_HUMAN		Ki	6.88	CHEMBL
Breakpoint cluster region protein	Kinase	P11274	BCR_HUMAN		Kd	5.39	CHEMBL
Serine/threonine-protein kinase 10	Kinase	O94804	STK10_HUMAN		Kd	6.10	CHEMBL
TRAF2 and NCK-interacting protein kinase	Kinase	Q9UKE5	TNIK_HUMAN		Kd	6.25	CHEMBL
Mitogen-activated protein kinase 14	Kinase	Q16539	MK14_HUMAN		Kd	6.66	CHEMBL

External reference:

ID	Source
EE083865G2	UNII
D09919	KEGG_DRUG
4034239	VUID
N0000191429	NUI
857890-39-2	SECONDARY_CAS_RN
4034239	VANDF
C2986924	UMLSCUI
CHEBI:85994	CHEBI
LEV	PDB_CHEM_ID
CHEMBL1289601	ChEMBL_ID
9823820	PUBCHEM_CID
DB09078	DRUGBANK_ID
CHEMBL2105704	ChEMBL_ID
9361	INN_ID
C531958	MESH_SUPPLEMENTAL_RECORD_UI
7426	IUPHAR_LIGAND_ID
1603296	RXNORM
232716	MMSL
294829	MMSL
294831	MMSL
30895	MMSL
d08346	MMSL
015899	NDDF
015900	NDDF
714108002	SNOMEDCT_US
714109005	SNOMEDCT_US
735068004	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Lenvima	HUMAN PRESCRIPTION DRUG LABEL	1	62856-704	CAPSULE	4 mg	ORAL	NDA	32 sections
Lenvima	HUMAN PRESCRIPTION DRUG LABEL	1	62856-704	CAPSULE	4 mg	ORAL	NDA	32 sections
Lenvima	HUMAN PRESCRIPTION DRUG LABEL	1	62856-704	CAPSULE	4 mg	ORAL	NDA	32 sections
Lenvima	HUMAN PRESCRIPTION DRUG LABEL	1	62856-708	CAPSULE	4 mg	ORAL	NDA	32 sections
Lenvima	HUMAN PRESCRIPTION DRUG LABEL	1	62856-708	CAPSULE	4 mg	ORAL	NDA	32 sections
Lenvima	HUMAN PRESCRIPTION DRUG LABEL	1	62856-708	CAPSULE	4 mg	ORAL	NDA	32 sections
Lenvima	HUMAN PRESCRIPTION DRUG LABEL	1	62856-710	CAPSULE	10 mg	ORAL	NDA	32 sections
Lenvima	HUMAN PRESCRIPTION DRUG LABEL	1	62856-710	CAPSULE	10 mg	ORAL	NDA	32 sections
Lenvima	HUMAN PRESCRIPTION DRUG LABEL	1	62856-710	CAPSULE	10 mg	ORAL	NDA	32 sections
Lenvima	HUMAN PRESCRIPTION DRUG LABEL	1	62856-712	CAPSULE	4 mg	ORAL	NDA	32 sections
Lenvima	HUMAN PRESCRIPTION DRUG LABEL	1	62856-712	CAPSULE	4 mg	ORAL	NDA	32 sections
Lenvima	HUMAN PRESCRIPTION DRUG LABEL	1	62856-712	CAPSULE	4 mg	ORAL	NDA	32 sections
Lenvima	HUMAN PRESCRIPTION DRUG LABEL	1	62856-720	CAPSULE	10 mg	ORAL	NDA	32 sections
Lenvima	HUMAN PRESCRIPTION DRUG LABEL	1	62856-720	CAPSULE	10 mg	ORAL	NDA	32 sections
Lenvima	HUMAN PRESCRIPTION DRUG LABEL	1	62856-720	CAPSULE	10 mg	ORAL	NDA	32 sections